India: "VIAGARA.IN" Goes Back To Pfizer

Last Updated: 14 June 2006
Article by Manisha Singh

Pfizer Products Inc., leading pharmaceutical company and manufacturers of VIAGRA filed an application for the grant of an interim injunction to restrain Altamash Khan and another party from using its registered trademark as under the domain name ‘’ and URL Altamash Khan claims to have acquired the domain name for sale and not to launch his own website. A latter application prayed that the domain name "" be transferred back to Pfizer, subject to the condition that incase the suit went against Pfizer, they would retransfer the domain name back to Altamash Khan. Pfizer also stated that in such an occurrence, they would bear all costs and expenses for the use of the domain name during the pendency of the suit and that they would suitably compensate them as may be determined by the Court.

The Counsel for Pfizer stating the nature of Viagra as a drug enhancing male potency, submitted that they were the owners of the mark. They contended that the Oxford dictionary too described the drug as stated alongside describing it as a trademark. They further submitted that the mark was registered in 147 countries and that their application in India was pending. The product’s recent launch further made it essential for the domain name to be available in order to respond to various queries regarding the product and to facilitate commercial transactions on the Internet. The counsel strengthened this contention by stating that just as businesses have physical addresses, they have a place in cyber space known as domain names. Placing reliance on Eicher Limited v. Web Link India, wherein the domain name was transferred back to Eicher Ltd., the Plaintiff prayed for similar relief.

Pfizer stated that the domain name, was already registered and that they possessed further domain name registrations, all of which prominently involved the trademark ‘VIAGRA’. They further contended, citing downloads from the .IN registry website, that .IN was a unique symbol of India; procedures for registering under the .IN domain were indicated in the Policy Framework and Implementation brought out by the Govt. of India under the Dept. of Information Technology.

Referring to various print outs from the IN Registry, he pointed out that the process of applications for registration of .IN domain names were divided into two periods. The first "Sunrise period" enabled registered trademark owners, companies and owners of intellectual property to protect their Domain names after verification. Thereon, the second period, enabled the general public to register their domain names. "DirectI", an accredited Registrar, had authorized Altamash Khan as its reseller. Altamash Khan had acquired the domain name in contention for this very resale purpose.

In order to prevent hoarding, auctioning, or selling .IN domain names at prices higher than usually charges, and to resolve other related disputes, a scheme known as .IN Domain Name Dispute Resolution Policy (INDRP) had been formulated. Any person who considered his legitimate rights or interests to be conflicted by a certain domain name could file a complaint under this scheme. The dispute though must have been referred to the arbitrators under INDRP; this system not having been in place was brought forth the High Court of Delhi.

The counsel for Altamash Khan contended that Pfizer though was aware of its capability to register in the ‘Sunrise’ period, such a procedure not being carried out was a failure on their part. It was further contended that the scheme been thrown open to the general public, Altamash Khan had taken quick action. Further it was contended that the registrations under the second module were made through accredited registrars, on a ‘first come first serve’ basis, and the same was done for and on the instructions of a customer. Altamash Khan stated that he had nothing more to do with the domain name except that he was a channel for the customer to register the same.

Altamash Khan further stated that the status of the domain ‘’ applied for, was shown to be inactive. They further submitted that it was not that Pfizer did not get any domain name, rather was capable of registration under the domain, and that too under the general policy. They also stated that the domain was registered with another applicant. They concluded that the domain names were open to the public and hence no order directing them to transfer the said domain name ought to be passed.

The Court took note of the fact that Pfizer was the owner of the trademark VIAGRA in 147 countries and its application in India was pending. Admitting that Pfizer had spent a lot of time, money and effort in developing the product and the trademark worldwide. The court held that with such genuine reputation worldwide and being the registered owner of the domain name, Pfizer did possess a legitimate interest in protecting its brand.

The court further stated that Altamash Khan had no interest in the domain name apart from putting it up for sale. Neither Altamash Khan nor his customer possess any interest whatsoever in VIAGRA as a product. The domain name was said to be confusingly similar to Pfizer’s and that they held no legitimate interest in respect of the domain

The domain name ‘’ being inactive, it was stated by the Hon’ble court that Altamash Khan was cyber squatting, over an address over which the rights and interests of Pfizer outweighed those of Altamash Khan. On these accounts, the domain name was ordered to be transferred back to Pfizer during the pendency of the suit, since no damages as such would be caused to Altamash khan. On the other hand, Pfizer in the event of the transfer being denied would have suffered serious injury in the shape of lost opportunity of commerce, development of the product, and interaction with Internet users, which might not be quantified in monetary terms.

Stating that Pfizer had a strong prima facie case, and the balance of convenience being in its favour, the court ordered the transfer of the domain name subject to the final decision. A condition was laid down that in case the final suit got decided against Pfizer, they would be liable to re-transfer the same and compensate the opposing party as directed by the Court. The Court also directed Pfizer to reimburse all costs and expenses incurred by Altamash Khan in obtaining the said domain name.

© Lex Orbis 2006

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions